A large unilateral basal cell carcinoma treated with Hedgehog inhibitor sonidegib: a case report
https://doi.org/10.4081/dr.2024.10152
Accepted: 15 October 2024
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Basal cell carcinoma (BCC) is the most common non-melanoma skin cancer. BCCs are categorized into “easy-to-treat” and “difficult-to-treat” groups, with the latter including all BCCs that are challenging to manage due to technical, patient-related, or tumor-related factors, such as locally advanced BCCs. In this report, we describe an 84-year-old patient with an extensive, unilateral BCC. Following a decision by the multidisciplinary skin cancer board, the patient was successfully treated with a daily dose of 200 mg of sonidegib, an inhibitor of the Hedgehog pathway, for eight months, acquiring complete clinical and histopathological remission. No significant side effects were reported. The follow-up period of 24 months has shown no negative results.
Peris K, Fargnoli MC, Kaufmann R, et al. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023. Eur J Cancer 2023;192:113254. DOI: https://doi.org/10.1016/j.ejca.2023.113254
Reifenberger J, Wolter M, Knobbe CB, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 2005;152:43-51. DOI: https://doi.org/10.1111/j.1365-2133.2005.06353.x
Gambini D, Passoni E, Nazzaro G, et al. Basal Cell Carcinoma and Hedgehog Pathway Inhibitors: Focus on Immune Response. Front Med (Lausanne) 2022;9:893063 DOI: https://doi.org/10.3389/fmed.2022.893063
Dika E, Scarfì F, Ferracin M, et al. Basal Cell Carcinoma: A Comprehensive Review. Int J Mol Sci 2020;21:5572. DOI: https://doi.org/10.3390/ijms21155572
Athar M, Li C, Kim AL, et al. Sonic hedgehog signaling in Basal cell nevus syndrome. Cancer Res 2014;74:4967-75. DOI: https://doi.org/10.1158/0008-5472.CAN-14-1666
Khamaysi Z, Bochner R, Indelman M, et al. Segmental basal cell naevus syndrome caused by an activating mutation in smoothened. Br J Dermatol 2016;175:178-81. DOI: https://doi.org/10.1111/bjd.14425
Saeidian AH, Cohen-Nowak A, O'Donnell M, et al. Linear basal cell nevus with a novel mosaic PTCH1 mutation. Exp Dermatol 2020;29:531-4. DOI: https://doi.org/10.1111/exd.14101
Nazzaro G, Benzecry V, Mattioli MA, et al. E. Sonidegib in Locally Advanced Basal Cell Carcinoma: A Monocentric Retrospective Experience and a Review of Published Real-Life Data. Cancers (Basel) 2023;15:3621. DOI: https://doi.org/10.3390/cancers15143621
Bossi P, Ascierto PA, Basset-Seguin N, et al. Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors. Crit Rev Oncol Hematol 2023;189:104066. DOI: https://doi.org/10.1016/j.critrevonc.2023.104066
Dasgeb B, Pajouhanfar S, Jazayeri A, et al. Novel PTCH1 and concurrent TP53 mutations in four patients with numerous non-syndromic basal cell carcinomas: The paradigm of oncogenic synergy. Exp Dermatol 2022;31:736-42. DOI: https://doi.org/10.1111/exd.14510
Kilgour JM, Jia JL, Sarin KY. Review of the Molecular Genetics of Basal Cell Carcinoma; Inherited Susceptibility, Somatic Mutations, and Targeted Therapeutics. Cancers (Basel) 2021;13:3870. DOI: https://doi.org/10.3390/cancers13153870
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
